相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
Moran Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
Bin Du et al.
CANCER LETTERS (2020)
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
Jenna H. Newman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Rachael M. Zemek et al.
FRONTIERS IN IMMUNOLOGY (2020)
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
Rachael M. Zemek et al.
NATURE PROTOCOLS (2020)
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
Nicola Principe et al.
FRONTIERS IN IMMUNOLOGY (2020)
Association of CXCL13 and Immune Cell Infiltration Signature in Clear Cell Renal Cell Carcinoma
Fangdong Jiao et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Independent drug action and its statistical implications for development of combination therapies
Cong Chen et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Determining cell type abundance and expression from bulk tissues with digital cytometry
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2019)
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
Marcelo G. Kazanietz et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Xavier Tekpli et al.
NATURE COMMUNICATIONS (2019)
Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
Natasha K. Brockwell et al.
NPJ PRECISION ONCOLOGY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Inference of immune cell composition on the expression profiles of mouse tissue
Ziyi Chen et al.
SCIENTIFIC REPORTS (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer
Martin Scurr et al.
CLINICAL CANCER RESEARCH (2017)
Microbiota: a key orchestrator of cancer therapy
Soumen Roy et al.
NATURE REVIEWS CANCER (2017)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Tumor-necrosis factor impairs CD4+ T cell-mediated immunological control in chronic viral infection
Marc Beyer et al.
NATURE IMMUNOLOGY (2016)
High-quality full-length immunoglobulin profiling with unique molecular barcoding
M. A. Turchaninova et al.
NATURE PROTOCOLS (2016)
STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer
Katrina K. Au et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)
Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts
Joshua C. Doloff et al.
BMC CANCER (2015)
A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
M. Koti et al.
BRITISH JOURNAL OF CANCER (2015)
MiXCR: software for comprehensive adaptive immunity profiling
Dmitriy A. Bolotin et al.
NATURE METHODS (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
W. Joost Lesterhuis et al.
SCIENTIFIC REPORTS (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Causal analysis approaches in Ingenuity Pathway Analysis
Andreas Kraemer et al.
BIOINFORMATICS (2014)
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer
Xin Chen et al.
PLOS ONE (2014)
Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy
Gautier Stoll et al.
ONCOIMMUNOLOGY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
Shiwen Peng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
Federica Moschella et al.
CLINICAL CANCER RESEARCH (2013)
Cyclophosphamide Promotes Chronic Inflammation-Dependent Immunosuppression and Prevents Antitumor Response in Melanoma
Alexandra Sevko et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation
Karin Breuer et al.
NUCLEIC ACIDS RESEARCH (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial
Kui Shen et al.
BMC MEDICAL GENOMICS (2012)
Double-Stranded RNA Induces Biphasic STAT1 Phosphorylation by both Type I Interferon (IFN)-Dependent and Type I IFN-Independent Pathways
Junichi Dempoya et al.
JOURNAL OF VIROLOGY (2012)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
Takayuki Iwamoto et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Nathan R. West et al.
BREAST CANCER RESEARCH (2011)
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs
Takeshi Nakahara et al.
BLOOD (2010)
Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination
Vedran Radojcic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
Vlad Popovici et al.
BREAST CANCER RESEARCH (2010)
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Robbert G. van der Most et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing
J. Douglas Freeman et al.
GENOME RESEARCH (2009)
Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth
Robbert G. van der Most et al.
PLOS ONE (2009)
GSEA-P:: A desktop application for Gene Set Enrichment Analysis
Aravind Subramanian et al.
BIOINFORMATICS (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration
Laura Bracci et al.
CLINICAL CANCER RESEARCH (2007)
Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells
Sven Brode et al.
JOURNAL OF IMMUNOLOGY (2006)
Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis
CL Wilson et al.
BIOINFORMATICS (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
P Matar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer:: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medical research council
R de Wit et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice:: implications for strategies of chemoimmunotherapy of cancer
G Schiavoni et al.
BLOOD (2000)
分享论文
